Datacubed Health Launches eClinical Platform App in China, Ensuring Full Compliance and Accessibility
Datacubed Health and AppInChina Forge Strategic Partnership to Launch eClinical Platform in China
New York, New York, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Datacubed Health, a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, is excited to announce the official launch of its eClinical platform app in China. This milestone achievement represents a significant step forward for Datacubed Health's commitment to expanding its presence in the Chinese market.
As part of this strategic move, Datacubed Health has joined forces with AppInChina, a renowned leader in Android App Store publication, ensuring seamless deployment of the eClinical platform app in official Android stores across China and the Apple App Store. This partnership guarantees accessibility to a wide range of devices and ecosystems.
Kyle Hogan, President of Datacubed Health, emphasized the importance of this collaboration: "Our partnership with AppInChina has been instrumental in ensuring the smooth launch of our eClinical platform app in China. This strategic alliance allows us to reach a broader audience while maintaining compliance with local regulations, which is essential for our growth in this market."
In preparation for this momentous launch, Datacubed Health has established a legal entity within China and acquired all necessary commercial and legal licenses and certificates. These crucial steps are a testament to Datacubed Health's commitment to providing secure and regulated services within the Chinese market.
Brett Kleger, CEO of Datacubed Health, stated, "Our investment in establishing a legal presence and obtaining the requisite licenses underscores our dedication to operating ethically and responsibly in China. We are focused on delivering cutting-edge solutions while adhering to local regulations and standards."
Moreover, Datacubed Health has undertaken comprehensive efforts to ensure full software compliance with Chinese regulations. The eClinical platform app for China has been meticulously customized to align with local requirements and has undergone rigorous testing by local quality assurance teams. This meticulous approach ensures the seamless functioning of the platform while adhering to Chinese network security requirements and restrictions.
Datacubed Health has also bolstered its presence in China by establishing a fully compliant and fault-tolerant Software as a Service (SaaS) infrastructure. The Datacubed China solution is now hosted in AWS Beijing, ensuring data security and reliability for users in the region.
With these key developments in operational, legal, and software compliance, Datacubed Health is well-prepared to provide unmatched support to clinical research efforts in China. The launch of the eClinical platform app represents a significant stride in bridging the gap between global research initiatives and the Chinese healthcare landscape.
In the words of CEO Brett Kleger: "We are thrilled to introduce Datacubed Health's eClinical platform app to the Chinese market. Our partnership with AppInChina, legal entity establishment, and rigorous compliance efforts demonstrate our dedication to providing world-class services to our Chinese users. We look forward to empowering clinical research initiatives in China with our cutting-edge solutions."
To learn more, we invite you to join us at Booth #24 at the 11th Annual Outsourcing in Clinical Trials Southern California 2023 from September 26-27 in San Diego, California, or visit our website at www.datacubed.com.
About Datacubed Health:
Datacubed Health is a pioneering eClinical technology company built from the ground up by industry veterans who wanted to create a better clinical trial experience for all stakeholders. Our solutions are all infused with neuroeconomic principles designed to be inclusive, drive compliance, and greatly improve retention. We strive to deliver the best experience for you and your patients through ease of use and flexible technology configurable to your needs. Our offerings include a Decentralized Trials Platform, eCOA/ePRO, Patient Engagement, eConsent, Medication Adherence, Televisits, and Geofencing. Learn more at www.datacubed.com.
Catalytic Agency for Datacubed Health
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nyxoah Strengthens its Executive Leadership Team28.11.2023 22:30:00 CET | Press release
Nyxoah Strengthens its Executive Leadership Team Francis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah’s Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector. Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market. “Nyxoah is entering the most exciting time in the Company’s history, with data fro
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update28.11.2023 22:15:00 CET | Press release
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European CommissionApprovability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024Management will conduct a business update conference call and live webcast on Thursday November 29, 2023, at 8:00 am ET (13:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2023 and pr
RÄTTELSE: Saknad MAR-etikett i tidigare pressmeddelande – ”Anoto ingår ett avtal för 1,1 miljoner USD avseende försäljning av pennor och treåriga mjukvarulicenser med Deutsche Telekom”28.11.2023 19:15:00 CET | Pressemelding
Anoto Group AB (publ) utfärdar en rättelse av pressmeddelandet som publicerades tidigare idag. Rättelsen avser att pressmeddelandet saknade MAR-etikett med hänvisning till EU:s marknadsmissbruksförordning (MAR). Följande information skulle ha varit med i pressmeddelandet: ”Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 28 november 2023, kl. 08:00 CEST.” Nedan publiceras det korrekta pressmeddelandet i sin helhet. Stockholm den 28 november 2023 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar idag att bolaget har tecknat ett upphandlingsavtal som avser försäljning av nya pennor, samt ett treårigt mjukvarulicensavtal med Deutsche Telekom AG (”Deutsche Telekom”). Deutsche Telekom är en av de äldsta kunderna inom Anotos affärssegment Forms och avtalet innebär att ramverket inom vilket Anoto och Deutsche T
CORRECTION: Missing MAR label in previous press release – “Anoto enters into a USD 1.1 million agreement for the sale of pens and three-year software licenses with Deutsche Telekom”28.11.2023 19:15:00 CET | Press release
Anoto Group AB (publ) issues a correction to the press release published earlier today. The correction refers to the fact that the press release lacked a MAR label with reference to the EU Market Abuse Regulation (MAR). The following information should have been included in the press release: ”This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication 28 November 2023, at 08:00 CEST.” The correct press release is published in its entirety below. Stockholm, 28 November 2023 – Anoto Group AB (publ) ("Anoto" or the "Company") today announces that it has signed a procurement agreement relating to the sale of new pens, plus a new three-year software licensing agreement with Deutsche Telekom AG (“Deutsche Telekom”). Deutsche Telekom is one of the oldest customers of Anoto’s Forms business and this agreement means that the framework withi
Status for Selskabets tilgodehavende hos Portinho S.A.28.11.2023 18:30:48 CET | pressemeddelelse
28. november 2023 Meddelelse nr. 46 Status for Selskabets tilgodehavende hos Portinho S.A. Selskabets bestyrelse, valgt ind i forbindelse med at Selskabet blev omdannet til en lægemiddelvirksomhed, og direktion har i længere tid, haft en meget tæt dialog med ledelsen i Portinho S.A. om indfrielse af Selskabets tilgodehavende hos Portinho S.A., der stammer fra tiden før Selskabet blev omdannet til en lægemiddelvirksomhed. Selskabets bestyrelse og direktion har sideløbende allokeret betydelige ressourcer til at afdække, hvilke dispositioner der fra den tidligere ledelse oprindeligt førte til etableringen af tilgodehavendet samt rationalet for de efterfølgende dispositioner af den tidligere ledelse, der har indvirket på tilgodehavendets vandring. Dette arbejde pågår forsat med blandt andet bistand fra både dansk og portugisisk juridisk rådgiver. Omfanget og vurderingen af de foreløbige resultater af undersøgelsesarbejdet har ført til, at det ikke længere er Selskabets vurdering, at tilgod